Cited by 122Psychedelics and Drug StudiesSchizophrenia research and treatmentNeurotransmitter Receptor Influence on Behavior

Mismatch negativity encoding of prediction errors predicts S-ketamine-induced cognitive impairments

Open access
Schmidt, André, Bachmann, Rosilla, Kometer, Michael, Csomor, Philipp A, Stephan, Klaas E, Seifritz, Erich, Vollenweider, Franz X·2012·Neuropsychopharmacology

Abstract

Psychotomimetics like the N-methyl-D-aspartate receptor (NMDAR) antagonist ketamine and the 5-hydroxytryptamine2A receptor (5-HT(2A)R) agonist psilocybin induce psychotic symptoms in healthy volunteers that resemble those of schizophrenia. Recent theories of psychosis posit that aberrant encoding of prediction errors (PE) may underlie the expression of psychotic symptoms. This study used a roving mismatch negativity (MMN) paradigm to investigate whether the encoding of PE is affected by pharmacological manipulation of NMDAR or 5-HT(2A)R, and whether the encoding of PE under placebo can be used to predict drug-induced symptoms. Using a double-blind within-subject placebo-controlled design, S-ketamine and psilocybin, respectively, were administrated to two groups of healthy subjects. Psychological alterations were assessed using a revised version of the Altered States of Consciousness (ASC-R) questionnaire. As an index of PE, we computed changes in MMN amplitudes as a function of the number of preceding standards (MMN memory trace effect) during a roving paradigm. S-ketamine, but not psilocybin, disrupted PE processing as expressed by a frontally disrupted MMN memory trace effect. Although both drugs produced positive-like symptoms, the extent of PE processing under placebo only correlated significantly with the severity of cognitive impairments induced by S-ketamine. Our results suggest that the NMDAR, but not the 5-HT(2A)R system, is implicated in PE processing during the MMN paradigm, and that aberrant PE signaling may contribute to the formation of cognitive impairments. The assessment of the MMN memory trace in schizophrenia may allow detecting early phases of the illness and might also serve to assess the efficacy of novel pharmacological treatments, in particular of cognitive impairments.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/npp.2011.261

Cites

93 of 93 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 94 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Schmidt, A., Bachmann, R., Kometer, M., Csomor, P. A., Stephan, K. E., Seifritz, E., & Vollenweider, F. X.
Affiliations
  • University of Zurich (CH)
  • Wellcome Centre for Human Neuroimaging (GB)
  • Psychiatrische Universitätsklinik Zürich (CH)
Corresponding author
Schmidt, André
Venue
Neuropsychopharmacology
Published
2011-10-26
Volume
37
Issue
4
Pages
865-875
ISSN
  • 0893-133X (ISSN-L)
  • 1740-634X
OpenAlex
W1989324273
Cited by
121
References
94
Citations by year
2026: 3 · 2025: 4 · 2024: 14 · 2023: 7 · 2022: 8 · 2021: 6 · 2020: 9 · 2019: 16 · 2018: 6 · 2017: 7 · 2016: 6 · 2015: 14 · 2014: 5 · 2013: 10 · 2012: 4
FWCI
6.55
Type
journal article
Language
en
Open access
Locations
  • Neuropsychopharmacology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
  • Zurich Open Repository and Archive (University of Zurich)
Funders
  • Wellcome Trust (091593)
  • SystemsX.ch
Topics
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords
mismatch negativity, esketamine, psilocybin, NMDA receptor antagonism, 5-HT2A receptor agonism, psychosis, cognitive impairment, schizophrenia
MeSH terms
Adult, Cognition Disorders, Double-Blind Method, Electroencephalography, Female, Forecasting, Humans, Ketamine, Male, Placebos, Psychoses, Substance-Induced, Schizophrenia, Receptors, N-Methyl-D-Aspartate, Excitatory Amino Acid Antagonists, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review